Please enable JavaScript to continue using this application.

Compare $HRTX vs $PTHS | Chartloom

Compare

$HRTX vs $PTHS

Heron Therapeutics Inc · Pelthos Therapeutics Inc

HRTX

Heron Therapeutics Inc

PTHS

Pelthos Therapeutics Inc

Compare $HRTX vs $PTHS

Comparing Heron Therapeutics Inc and Pelthos Therapeutics Inc

HRTXHeron Therapeutics Inc

PTHSPelthos Therapeutics Inc

HRTXHeron Therapeutics Inc

Market cap

$77M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

1.0%

YTD performance

-67.8%

52W performance

-69.9%

FCF yield

-15.8%

PTHSPelthos Therapeutics Inc

Market cap

$71M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.83x

Rev growth (TTM)

—

YTD performance

-30.4%

52W performance

-27.4%

FCF yield

-70.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

HRTX

PTHS

Detailed metrics comparison

HRTX

Heron Therapeutics Inc

PTHS

Pelthos Therapeutics Inc

Market Cap

HRTX$77M

PTHS$71M

Enterprise Value

HRTX$199M

PTHS$71M

Price

HRTX$0.41

PTHS$20.50

P/E Ratio

HRTXN/A

PTHSN/A

P/S Ratio

HRTX0.51x

PTHS1.65x

EV/Sales

HRTX1.31x

PTHS1.65x

EV/EBITDA

HRTX79.76x

PTHS0.00x

P/B Ratio

HRTX9.55x

PTHS2.03x

P/FCF Ratio

HRTXN/A

PTHSN/A

EV/FCF

HRTX-16.38x

PTHS-1.41x

PEG Ratio

HRTXN/A

PTHSN/A

Forward P/E (NTM)

HRTXN/A

PTHSN/A

Forward P/S (NTM)

HRTXN/A

PTHS0.83x

Revenue (TTM)

HRTX$151M

PTHS$43M

Revenue Growth (YoY)

HRTX1.0%

PTHSN/A

Forward Rev Growth

HRTX-1.6%

PTHS76.2%

Gross Margin (TTM)

HRTX70.1%

PTHS78.6%

Operating Margin (TTM)

HRTX0.0%

PTHS0.0%

EBITDA Margin (TTM)

HRTX-5.8%

PTHS-121.6%

Net Margin (TTM)

HRTX-22.5%

PTHS-165.2%

FCF Margin (TTM)

HRTX-8.0%

PTHS-116.6%

Net Income (TTM)

HRTX$-34M

PTHS$-72M

FCF (TTM)

HRTX$-12M

PTHS$-50M

EPS (TTM)

HRTX-$0.18

PTHS-$20.22

ROE (TTM)

HRTX-30090.0%

PTHS-7804.0%

ROA (TTM)

HRTX-1357.0%

PTHS-6701.0%

ROIC (TTM)

HRTX-2233.0%

PTHS-5896.0%

Cash

HRTX$21M

PTHS$0

Debt

HRTX$143M

PTHS$0

Net Cash/Debt

HRTX$-122M

PTHS$0

Current Ratio (TTM)

HRTX2.49x

PTHS2.05x

Quick Ratio (TTM)

HRTX1.44x

PTHS1.10x

Debt/Equity (TTM)

HRTX20.65x

PTHS0.81x

Debt/Assets (TTM)

HRTX0.0%

PTHS0.0%

Interest Coverage (TTM)

HRTXN/A

PTHSN/A

Net Debt/EBITDA (TTM)

HRTX0.00x

PTHS0.00x

Beta

HRTX1.65

PTHS3.13

52W Performance

HRTX-69.9%

PTHS-27.4%

YTD Performance

HRTX-67.8%

PTHS-30.4%

% from 52W High

HRTX-74.3%

PTHS-45.3%

% from 52W Low

HRTX55.6%

PTHS12.7%

Asset Turnover (TTM)

HRTX0.60x

PTHS0.00x

FCF Yield (TTM)

HRTX-15.8%

PTHS-70.8%

Earnings Yield (TTM)

HRTX-44.3%

PTHS-100.3%

Dividend Yield (TTM)

HRTXN/A

PTHSN/A

Rule of 40

HRTX-7.0

PTHS-116.6

EV/GP/RG

HRTXN/A

PTHS0.02

Ticker research

View HRTX research View PTHS research

Metric	HRTX Heron Therapeutics Inc	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$77M	$71M
Enterprise Value	$199M	$71M
Price	$0.41	$20.50
P/E Ratio	N/A	N/A
P/S Ratio	0.51x	1.65x
EV/Sales	1.31x	1.65x
EV/EBITDA	79.76x	0.00x
P/B Ratio	9.55x	2.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-16.38x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.83x
Revenue & Growth
Revenue (TTM)	$151M	$43M
Revenue Growth (YoY)	1.0%	N/A
Forward Rev Growth	-1.6%	76.2%
Profitability
Gross Margin (TTM)	70.1%	78.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-5.8%	-121.6%
Net Margin (TTM)	-22.5%	-165.2%
FCF Margin (TTM)	-8.0%	-116.6%
Net Income (TTM)	$-34M	$-72M
FCF (TTM)	$-12M	$-50M
EPS (TTM)	-$0.18	-$20.22
ROE (TTM)	-30090.0%	-7804.0%
ROA (TTM)	-1357.0%	-6701.0%
ROIC (TTM)	-2233.0%	-5896.0%
Financial Health
Cash	$21M	$0
Debt	$143M	$0
Net Cash/Debt	$-122M	$0
Current Ratio (TTM)	2.49x	2.05x
Quick Ratio (TTM)	1.44x	1.10x
Debt/Equity (TTM)	20.65x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.65	3.13
52W Performance	-69.9%	-27.4%
YTD Performance	-67.8%	-30.4%
% from 52W High	-74.3%	-45.3%
% from 52W Low	55.6%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	-15.8%	-70.8%
Earnings Yield (TTM)	-44.3%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-7.0	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View HRTX research	View PTHS research

Valuation

P/S Ratio

HRTX

0.51x

PTHS

1.65x

EV/FCF

HRTX

-16.38x

PTHS

-1.41x

Growth & revenue

Revenue Growth TTM

HRTX

1.0%

Forward Revenue Growth

PTHS

76.2%

HRTX

-1.6%

Profitability & performance

Gross Margin

PTHS

78.6%

HRTX

70.1%

ROE

PTHS

-7804.0%

HRTX

-30090.0%

FCF Yield %

HRTX

-15.8%

PTHS

-70.8%

52-Week Performance

PTHS

-27.4%

HRTX

-69.9%

Detailed metrics comparison

HRTX

Heron Therapeutics Inc

PTHS

Pelthos Therapeutics Inc

Market Cap

HRTX$77M

PTHS$71M

Enterprise Value

HRTX$199M

PTHS$71M

Price

HRTX$0.41

PTHS$20.50

P/E Ratio

HRTXN/A

PTHSN/A

P/S Ratio

HRTX0.51x

PTHS1.65x

EV/Sales

HRTX1.31x

PTHS1.65x

EV/EBITDA

HRTX79.76x

PTHS0.00x

P/B Ratio

HRTX9.55x

PTHS2.03x

P/FCF Ratio

HRTXN/A

PTHSN/A

EV/FCF

HRTX-16.38x

PTHS-1.41x

PEG Ratio

HRTXN/A

PTHSN/A

Forward P/E (NTM)

HRTXN/A

PTHSN/A

Forward P/S (NTM)

HRTXN/A

PTHS0.83x

Revenue (TTM)

HRTX$151M

PTHS$43M

Revenue Growth (YoY)

HRTX1.0%

PTHSN/A

Forward Rev Growth

HRTX-1.6%

PTHS76.2%

Gross Margin (TTM)

HRTX70.1%

PTHS78.6%

Operating Margin (TTM)

HRTX0.0%

PTHS0.0%

EBITDA Margin (TTM)

HRTX-5.8%

PTHS-121.6%

Net Margin (TTM)

HRTX-22.5%

PTHS-165.2%

FCF Margin (TTM)

HRTX-8.0%

PTHS-116.6%

Net Income (TTM)

HRTX$-34M

PTHS$-72M

FCF (TTM)

HRTX$-12M

PTHS$-50M

EPS (TTM)

HRTX-$0.18

PTHS-$20.22

ROE (TTM)

HRTX-30090.0%

PTHS-7804.0%

ROA (TTM)

HRTX-1357.0%

PTHS-6701.0%

ROIC (TTM)

HRTX-2233.0%

PTHS-5896.0%

Cash

HRTX$21M

PTHS$0

Debt

HRTX$143M

PTHS$0

Net Cash/Debt

HRTX$-122M

PTHS$0

Current Ratio (TTM)

HRTX2.49x

PTHS2.05x

Quick Ratio (TTM)

HRTX1.44x

PTHS1.10x

Debt/Equity (TTM)

HRTX20.65x

PTHS0.81x

Debt/Assets (TTM)

HRTX0.0%

PTHS0.0%

Interest Coverage (TTM)

HRTXN/A

PTHSN/A

Net Debt/EBITDA (TTM)

HRTX0.00x

PTHS0.00x

Beta

HRTX1.65

PTHS3.13

52W Performance

HRTX-69.9%

PTHS-27.4%

YTD Performance

HRTX-67.8%

PTHS-30.4%

% from 52W High

HRTX-74.3%

PTHS-45.3%

% from 52W Low

HRTX55.6%

PTHS12.7%

Asset Turnover (TTM)

HRTX0.60x

PTHS0.00x

FCF Yield (TTM)

HRTX-15.8%

PTHS-70.8%

Earnings Yield (TTM)

HRTX-44.3%

PTHS-100.3%

Dividend Yield (TTM)

HRTXN/A

PTHSN/A

Rule of 40

HRTX-7.0

PTHS-116.6

EV/GP/RG

HRTXN/A

PTHS0.02

Ticker research

View HRTX research View PTHS research

Metric	HRTX Heron Therapeutics Inc	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$77M	$71M
Enterprise Value	$199M	$71M
Price	$0.41	$20.50
P/E Ratio	N/A	N/A
P/S Ratio	0.51x	1.65x
EV/Sales	1.31x	1.65x
EV/EBITDA	79.76x	0.00x
P/B Ratio	9.55x	2.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-16.38x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.83x
Revenue & Growth
Revenue (TTM)	$151M	$43M
Revenue Growth (YoY)	1.0%	N/A
Forward Rev Growth	-1.6%	76.2%
Profitability
Gross Margin (TTM)	70.1%	78.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-5.8%	-121.6%
Net Margin (TTM)	-22.5%	-165.2%
FCF Margin (TTM)	-8.0%	-116.6%
Net Income (TTM)	$-34M	$-72M
FCF (TTM)	$-12M	$-50M
EPS (TTM)	-$0.18	-$20.22
ROE (TTM)	-30090.0%	-7804.0%
ROA (TTM)	-1357.0%	-6701.0%
ROIC (TTM)	-2233.0%	-5896.0%
Financial Health
Cash	$21M	$0
Debt	$143M	$0
Net Cash/Debt	$-122M	$0
Current Ratio (TTM)	2.49x	2.05x
Quick Ratio (TTM)	1.44x	1.10x
Debt/Equity (TTM)	20.65x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.65	3.13
52W Performance	-69.9%	-27.4%
YTD Performance	-67.8%	-30.4%
% from 52W High	-74.3%	-45.3%
% from 52W Low	55.6%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	-15.8%	-70.8%
Earnings Yield (TTM)	-44.3%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-7.0	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View HRTX research	View PTHS research